Dennis Henner Net Worth

The estimated Net Worth of Dennis Henner is at least $92.5 Milión dollars as of 2 July 2018. Dennis Henner owns over 200,000 units of Rigel Pharmaceuticals stock worth over $49,505,854 and over the last 21 years Dennis sold RIGL stock worth over $42,968,350.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dennis Henner RIGL stock SEC Form 4 insiders trading

Dennis has made over 19 trades of the Rigel Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently Dennis bought 200,000 units of RIGL stock worth $3,200,000 on 2 July 2018.

The largest trade Dennis's ever made was selling 868,055 units of Rigel Pharmaceuticals stock on 23 November 2004 worth over $20,390,612. On average, Dennis trades about 101,751 units every 238 days since 2004. As of 2 July 2018 Dennis still owns at least 3,816,951 units of Rigel Pharmaceuticals stock.

You can see the complete history of Dennis Henner stock trades at the bottom of the page.

What's Dennis Henner's mailing address?

Dennis's mailing address filed with the SEC is C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE, 31ST FLOOR, BOSTON, MA, 02199.

Insiders trading at Rigel Pharmaceuticals

Over the last 21 years, insiders at Rigel Pharmaceuticals have traded over $170,041,384 worth of Rigel Pharmaceuticals stock and bought 2,068,700 units worth $7,281,949 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke a Partners L P/Ilbiotechnolog.... On average, Rigel Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $961,207. The most recent stock trade was executed by David A Santos on 2 February 2024, trading 14,519 units of RIGL stock currently worth $16,552.

What does Rigel Pharmaceuticals do?

rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.

Complete history of Dennis Henner stock trades at Rigel Pharmaceuticals

Rigel Pharmaceuticals executives and stock owners

Rigel Pharmaceuticals executives and other stock owners filed with the SEC include:

• David A. Santos,
  Exec. VP & Chief Commercial Officer
• Raul R. Rodriguez,
  Pres, CEO & Director
• Dolly A. Vance,
  Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
• Dr. Wolfgang Dummer M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Dean L. Schorno CPA,
  Exec. VP & CFO
• Julie Patel,
  Sr. VP of HR
• Tarek Sallam,
  VP of Marketing
• Dr. Esteban S. Masuda,
  Exec. VP of Research
• Joseph Lasaga,
  Sr. VP of Corp. Devel.
• Gary A Lyons,
  
• Brian L. Kotzin,
  
• Jane Wasman,
  
• Kamil Ali Jackson,
  
• Donald G Payan,
  Executive V.P. and CSO
• Peter S Ringrose,
  Director
• Keith Katkin,
  Director
• Ryan D Maynard,
  VP Finance, Acting CFO
• Esteban Masuda,
  Sr. VP Research
• Walter H Moos,
  
• Bradford S Goodwin,
  Director
• Stephen A Sherwin,
  Director
• Eldon C. Iii Mayer,
  EVP & Chief Commercial Officer
• James H Welch,
  VP, CFO and Corp Secretary
• Alan D Frazier,
  Director
• Elliot B Grossbard,
  Sr VP of Med Development
• Anthony Gregg Lapointe,
  
• Nelson Cabatuan,
  VP,Finance & Princ.Acctg. Off.
• Stacy Markel,
  EVP Human Resources
• Joseph Lasaga,
  Sr.VP Bus.Dev.Alliance Mgmt.
• Anne Marie Duliege,
  EVP & Chief Medical Officer
• Partners Ii Incalta Biophar...,
  
• Nicholas J Iii Simon,
  Director
• Bioventures Iii Qp Lpmpm Bi...,
  
• Lukegadicke Ansbert Evnin,
  
• Dennis Henner,
  Director
• Jeanalta Partnersalta Calif...,
  
• Nicholas Galakatos,
  10% owner
• Michael Steinmetz,
  10% owner
• Partners Ii Incalta Biophar...,
  
• Ansbert Gadicke,
  10% owner
• Luke Evnin,
  10% owner
• Bioequities Master Fund Lpm...,
  
• Healthcare Iv Lpfhm Iv Lpfh...,
  
• Lisa Rojkjaer,
  EVP, Chief Medical Officer
• James M Gower,
  CEO and Chairman of the Board
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Hollings Renton,
  Director
• James Edeerfield Capital Lp...,
  
• James Edeerfield Capital Lp...,
  
• Jean Deleage,
  Director
• Robin D G Cooper,
  Sr. V.P. Pharmaceutical Scs.
• David A Santos,
  EVP, Chief Commercial Officer
• Wolfgang Dummer,
  EVP & CMO
• Alison L. Hannah,
  
• Dean L Schorno,
  EVP & Chief Financial Officer
• Dolly Vance,
  EVP Corp. Affairs, G.C., Sect.
• Raymond J. Furey,
  EVP, GC, CCO & Corp Sec